Syncona Limited (LON:SYNC), a leading healthcare company focused on creating, building and scaling a portfolio of global leaders in life science, has noted that its portfolio company, Anaveon, has announced that it will present updated clinical data from the ongoing Phase I dose escalation study of ANV419 in patients with solid tumours in a poster at the European Society of Medical Oncology (ESMO) annual meeting. ANV419 is a selective interleukin-2 (IL-2) agonist, a type of protein which has the potential to therapeutically enhance a patient’s immune system to respond to tumours. It has been designed to overcome known challenges with approved IL-2 therapies and enable the delivery of high dose IL-2 to patients in a way which addresses safety, tolerability and durability issues seen elsewhere in its use.
Highlights from the poster presentation include:
· Overall, ANV419 continues to demonstrate a potentially differentiated safety profile to approved IL-2 therapies
· ANV419, at a dose of 243 µg/kg every two weeks, was determined as the recommended Phase II dose
· The study determined that one injection of ANV419 at this dose level delivers more IL-2 exposure than a full cycle of an approved IL-2 therapy (high dose aldesleukin)
· A durable response was observed in one patient with advanced immunotherapy-resistant non-small cell lung cancer (NSCLC)
· Details of the poster are copied below, with further detail available in the abstract on the ESMO website
Martin Murphy, Chair of Syncona Investment Management Limited, said: “The data which will be presented at ESMO further underlines the strong safety and tolerability profile of ANV419, demonstrating potential differentiation from other IL-2 therapies. We are encouraged by the NSCLC patient who has demonstrated a durable response and now await the full efficacy read-out in the ongoing monotherapy trial in melanoma at the recommended Phase II dose.”
Poster # 1031P: ANV419, a selective IL-2Rβ/γ agonist in patients with relapsed/refractory advanced solid tumours
Authors: E. Calvo, M. Joerger, H. Läubli, J. Lopez, G. Alonso Casal, E. Corral, D. Hess, D. König, V. S. Perez, E. Gasal, S. Jethwa, D. Di Blasi, E. Garralda
Date and Time: Monday, October 23, 2023, at 11:00am-12:00pm BST / 12:00pm-1:00 pm (CEST),
The accompanying poster will be on display on the ESMO 2023 meeting platform as well as on Anaveon’s website from October 23, 2023.
